These results might be important in the context of the new passive immunotherapy era in AD and open the possibility to combine the use of Aβ monoclonal antibodies with therapies that promote an increase of circulating ApoJ, with the aim to protect the cerebrovasculature and reduce the risk of ARIA. Here, CLU is linked to Alzheimer disease.